Kinnate Biopharma Inc. (KNTE) NASDAQ
$2.65 - (-)
Market Cap: -
As of 04/02/24 12:00 AM EDT. Market closed.
Kinnate Biopharma Inc. (KNTE)
NASDAQ
$2.65
- (-)
Market Cap: -
As of 04/02/24 12:00 AM EDT. Market closed.
Add to Portfolio
kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Nima Farzan
URL
Address
103 Montgomery Street, Suite 150, CA, San Francisco, 94129.
PRICE CHART FOR KINNATE BIOPHARMA INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$2.65
Days Range
$2.64 - $2.67
52 week range
- - -
Volume
2,812,224
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
47,225,312
Open
-
Previous Close
$2.65
Days Range
$2.64 - $2.67
52 week range
- - -
Volume
2,812,224
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
47,225,312
FINANCIAL STATEMENTS FOR KINNATE BIOPHARMA INC
LOADING...
INSIDER TRANSACTIONS FOR KINNATE BIOPHARMA INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Williams Richard Thomas | Chief Medical Officer | Dec 01, 2023 | Option Exercise | $2.25 | 541 | 1,217 | 68,146 | Dec 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Dec 01, 2023 | Option Exercise | $2.25 | 1,459 | 3,283 | 65,593 | Dec 05, 2023, 05:00 PM |
Meltz Mark A | COO General Counsel Secretary | Dec 01, 2023 | Option Exercise | $2.25 | 541 | 1,217 | 28,136 | Dec 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Sep 01, 2023 | Option Exercise | $2.35 | 1,459 | 3,429 | 67,052 | Sep 06, 2023, 05:00 PM |
Meltz Mark A | COO General Counsel Secretary | Sep 01, 2023 | Option Exercise | $2.35 | 541 | 1,271 | 28,677 | Sep 06, 2023, 05:00 PM |
Williams Richard Thomas | Chief Medical Officer | Sep 01, 2023 | Option Exercise | $2.35 | 541 | 1,271 | 68,687 | Sep 06, 2023, 05:00 PM |
Williams Richard Thomas | Chief Medical Officer | Jun 01, 2023 | Option Exercise | $4.30 | 541 | 2,326 | 69,228 | Jun 05, 2023, 05:01 PM |
Meltz Mark A | COO General Counsel Secretary | Jun 01, 2023 | Option Exercise | $4.30 | 541 | 2,326 | 29,218 | Jun 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Jun 01, 2023 | Option Exercise | $4.30 | 1,459 | 6,274 | 68,511 | Jun 05, 2023, 05:00 PM |
Tananbaum James B. | Director | May 08, 2023 | Buy | $2.80 | 1,780,000 | 4,984,000 | 3,525,957 | May 10, 2023, 05:49 PM |
Foresite Capital Management IV, LLC | 10% Owner | May 08, 2023 | Buy | $2.80 | 1,780,000 | 4,984,000 | 3,525,957 | May 10, 2023, 05:42 PM |
ORBIMED ADVISORS LLC | Director | May 04, 2023 | Buy | $2.75 | 479,909 | 1,319,750 | 4,738,453 | May 08, 2023, 05:22 PM |
ORBIMED ADVISORS LLC | Director | May 05, 2023 | Buy | $2.82 | 981,023 | 2,766,485 | 1,368,339 | May 08, 2023, 05:22 PM |
GORDON CARL L | Director | May 05, 2023 | Buy | $2.82 | 981,023 | 2,766,485 | 1,368,339 | May 08, 2023, 05:11 PM |
GORDON CARL L | Director | May 04, 2023 | Buy | $2.75 | 479,909 | 1,319,750 | 4,738,453 | May 08, 2023, 05:11 PM |
GORDON CARL L | Director | May 02, 2023 | Buy | $2.67 | 338,262 | 903,160 | 4,425,462 | May 02, 2023, 09:38 PM |
GORDON CARL L | Director | May 01, 2023 | Buy | $2.62 | 716,157 | 1,876,331 | 4,204,852 | May 02, 2023, 09:38 PM |
GORDON CARL L | Director | Apr 28, 2023 | Buy | $2.55 | 350,749 | 894,410 | 3,737,784 | May 02, 2023, 09:38 PM |
ORBIMED ADVISORS LLC | Director | May 02, 2023 | Buy | $2.67 | 338,262 | 903,160 | 4,425,462 | May 02, 2023, 09:34 PM |
ORBIMED ADVISORS LLC | Director | May 01, 2023 | Buy | $2.62 | 716,157 | 1,876,331 | 4,204,852 | May 02, 2023, 09:34 PM |
ORBIMED ADVISORS LLC | Director | Apr 28, 2023 | Buy | $2.55 | 350,749 | 894,410 | 3,737,784 | May 02, 2023, 09:34 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 01, 2023 | Option Exercise | $5.21 | 638 | 3,324 | 67,295 | Mar 03, 2023, 05:58 PM |
Meltz Mark A | COO General Counsel Secretary | Mar 01, 2023 | Option Exercise | $5.21 | 638 | 3,324 | 27,286 | Mar 03, 2023, 05:57 PM |
Krishnamohan Neha | Chief Financial Officer | Mar 01, 2023 | Option Exercise | $5.21 | 1,721 | 8,966 | 67,378 | Mar 03, 2023, 05:56 PM |
Williams Richard Thomas | Chief Medical Officer | Dec 01, 2022 | Option Exercise | $7.75 | 541 | 4,193 | 67,933 | Dec 02, 2022, 08:00 PM |
Krishnamohan Neha | Chief Financial Officer | Dec 01, 2022 | Option Exercise | $7.75 | 1,459 | 11,307 | 69,099 | Dec 02, 2022, 08:00 PM |
Meltz Mark A | COO General Counsel Secretary | Dec 01, 2022 | Option Exercise | $7.75 | 541 | 4,193 | 27,924 | Dec 02, 2022, 08:00 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 14, 2022 | Buy | $8.37 | 25,000 | 209,250 | 42,333 | Mar 15, 2022, 05:01 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 11, 2022 | Buy | $8.64 | 15,000 | 129,600 | 17,333 | Mar 15, 2022, 05:01 PM |
GORDON CARL L | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:51 PM |
GORDON CARL L | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:51 PM |
GORDON CARL L | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:51 PM |
ORBIMED ADVISORS LLC | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:42 PM |
ORBIMED ADVISORS LLC | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:42 PM |
ORBIMED ADVISORS LLC | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:42 PM |
Tananbaum James B. | Director | Dec 03, 2020 | Buy | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 09:39 PM |
Foresite Capital Management IV, LLC | 10% Owner | Dec 03, 2020 | Option Exercise | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 08:57 PM |
ORBIMED ADVISORS LLC | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 06:11 PM |
GORDON CARL L | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 05:13 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
Williams Richard Thomas | Chief Medical Officer | 12/01/2023 | 1,217 |
Krishnamohan Neha | Chief Financial Officer | 12/01/2023 | 3,283 |
Meltz Mark A | COO General Counsel Secretary | 12/01/2023 | 1,217 |
Krishnamohan Neha | Chief Financial Officer | 09/01/2023 | 3,429 |
Meltz Mark A | COO General Counsel Secretary | 09/01/2023 | 1,271 |
Williams Richard Thomas | Chief Medical Officer | 09/01/2023 | 1,271 |
Williams Richard Thomas | Chief Medical Officer | 06/01/2023 | 2,326 |
Meltz Mark A | COO General Counsel Secretary | 06/01/2023 | 2,326 |
Krishnamohan Neha | Chief Financial Officer | 06/01/2023 | 6,274 |
Tananbaum James B. | Director | 05/08/2023 | 4,984,000 |
Foresite Capital Management IV, LLC | 10% Owner | 05/08/2023 | 4,984,000 |
ORBIMED ADVISORS LLC | Director | 05/04/2023 | 1,319,750 |
ORBIMED ADVISORS LLC | Director | 05/05/2023 | 2,766,485 |
GORDON CARL L | Director | 05/05/2023 | 2,766,485 |
GORDON CARL L | Director | 05/04/2023 | 1,319,750 |
GORDON CARL L | Director | 05/02/2023 | 903,160 |
GORDON CARL L | Director | 05/01/2023 | 1,876,331 |
GORDON CARL L | Director | 04/28/2023 | 894,410 |
ORBIMED ADVISORS LLC | Director | 05/02/2023 | 903,160 |
ORBIMED ADVISORS LLC | Director | 05/01/2023 | 1,876,331 |
ORBIMED ADVISORS LLC | Director | 04/28/2023 | 894,410 |
Williams Richard Thomas | Chief Medical Officer | 03/01/2023 | 3,324 |
Meltz Mark A | COO General Counsel Secretary | 03/01/2023 | 3,324 |
Krishnamohan Neha | Chief Financial Officer | 03/01/2023 | 8,966 |
Williams Richard Thomas | Chief Medical Officer | 12/01/2022 | 4,193 |
Krishnamohan Neha | Chief Financial Officer | 12/01/2022 | 11,307 |
Meltz Mark A | COO General Counsel Secretary | 12/01/2022 | 4,193 |
Williams Richard Thomas | Chief Medical Officer | 03/14/2022 | 209,250 |
Williams Richard Thomas | Chief Medical Officer | 03/11/2022 | 129,600 |
GORDON CARL L | Director | 02/11/2022 | 1,594,320 |
GORDON CARL L | Director | 02/15/2022 | 89,640 |
GORDON CARL L | Director | 02/14/2022 | 305,486 |
ORBIMED ADVISORS LLC | Director | 02/15/2022 | 89,640 |
ORBIMED ADVISORS LLC | Director | 02/14/2022 | 305,486 |
ORBIMED ADVISORS LLC | Director | 02/11/2022 | 1,594,320 |
Tananbaum James B. | Director | 12/03/2020 | 20,000,000 |
Foresite Capital Management IV, LLC | 10% Owner | 12/03/2020 | 20,000,000 |
ORBIMED ADVISORS LLC | Director | 12/02/2020 | 15,000,000 |
GORDON CARL L | Director | 12/02/2020 | 15,000,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN KINNATE BIOPHARMA INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 7,559,729 | 0.39% | -5.62% | Other |
VIKING GLOBAL INVESTORS LP | 1,820,462 | 0.02% | No change | Growth At A Reasonable Price |
BLACKROCK INC. | 586,688 | 0.00004% | -20.86% | Other |
RENAISSANCE TECHNOLOGIES LLC | 574,979 | 0.00211% | 13.64% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 230,753 | 0.00006% | 4.17% | Other |
D. E. SHAW & CO., INC. | 150,695 | 0.00031% | 170.01% | Other |
CHANGE IN SHARES OUTSTANDING FOR KINNATE BIOPHARMA INC
STOCK BUYBACKS FOR KINNATE BIOPHARMA INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.06%
1Q
06/30/2023
1.00%
2Q
03/31/2023
3.77%
3Q
12/31/2022
6.56%
4Q
09/30/2022
6.73%
5Q
06/30/2022
7.09%
6Q
03/31/2022
7.38%
7Q
12/31/2021
7.77%
8Q
09/30/2021
7.92%
9Q
06/30/2021
8.24%
10Q
03/31/2021
8.38%
11Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR KINNATE BIOPHARMA INC
LOADING...